Lori Bruce, D.Bioethics, MA, HEC-C. February 2025

Transcript

• 00:00Jessica, why don't you,
• 00:03start the recording?
• 00:05All set.
• 00:07Okay.
• 00:08So welcome, everyone. Good to
• 00:10see,
• 00:11so many people here today.
• 00:14This is our January meeting,
• 00:16first meeting of twenty twenty
• 00:17five for our monthly psychedelic
• 00:19seminar.
• 00:21Next month, we'll meet on,
• 00:24I I believe it'll be
• 00:25the third Friday. We'll confirm
• 00:26the def the the time
• 00:28for sure, but we have
• 00:29a tentative commitment to hear
• 00:30from Al Kay next week
• 00:31about some of the neurobiological
• 00:33findings and psychedelic effects that
• 00:34he's discovering in his lab,
• 00:36which will be a a
• 00:37contrast to today and I
• 00:38think, really interesting.
• 00:40Yeah. But today will probably
• 00:42be the second Friday, Chris.
• 00:44Second Friday. Good.
• 00:46We'll let everyone know. And
• 00:47then we'll go back to
• 00:48the third Friday. We'll confirm
• 00:49and send out. Yeah. Thank
• 00:50you.
• 00:52But today, we have a
• 00:53treat. We have Laurie Bruce,
• 00:55with us who, is on
• 00:56the faculty
• 00:57here at Yale. She got
• 00:58her doctorate in bioethics,
• 01:02and is the associate director
• 01:03of the Yale Interdisciplinary
• 01:05Center for Bioethics.
• 01:06She's a key researcher at
• 01:08the Oxford,
• 01:09NUS Center for Neuroethics and
• 01:11Society, and she's the chair
• 01:13of the Community Bioethics Forum
• 01:14at the Yale School of
• 01:15Medicine.
• 01:16She's also served on pediatric
• 01:17and adults ethics committees at
• 01:19Harvard and at Yale for
• 01:20over fifteen years. And she's
• 01:22worked in many areas of
• 01:23bioethics, but of most relevance
• 01:25for us today, she's done
• 01:26a lot of work on
• 01:27the ethics of psychedelics and
• 01:28interacting issues on the ethics,
• 01:30ethical dimensions of bodily autonomy
• 01:33in clinical practice, as well
• 01:34as in law and popular
• 01:35culture.
• 01:36Her work often centers in
• 01:37amplifying the voices and values
• 01:39of community members in health
• 01:40policy,
• 01:41including work on consent, harm
• 01:43reduction, and on infant abandonment.
• 01:45She teaches courses,
• 01:47at Yale and elsewhere in
• 01:48ethical policy making, which are
• 01:50informed by her legislative successes
• 01:52at the state and federal
• 01:53levels. She also directs Yale's
• 01:55Summer Institute in Bioethics.
• 01:56Her work, in addition to,
• 01:58many publications, has been covered
• 02:00in media outlets such as
• 02:01NBC Nightly News, The New
• 02:02York Times, CNN, Time Magazine,
• 02:04and The Boston Globe.
• 02:06So this will be a
• 02:08treat today,
• 02:09and she's gonna be talking
• 02:10to us about the regulatory
• 02:11environment, how it might change,
• 02:12and what the implications of
• 02:13that are. So, Laurie, thanks
• 02:15so much for being with
• 02:16us. Look very much looking
• 02:17forward to your talk and
• 02:18discussion.
• 02:19Thanks so much, Chris, for
• 02:21the warm welcome and for
• 02:22this invitation.
• 02:23It's, great to see
• 02:25everyone here.
• 02:27And,
• 02:28so,
• 02:29today,
• 02:31I'll be talking about psychedelics
• 02:33and a deregulated
• 02:35policy climate,
• 02:36what twenty twenty five might
• 02:37bring.
• 02:40I
• 02:40enter this lens, from harm
• 02:43reduction,
• 02:44from,
• 02:45my
• 02:46hat as a bioethicist.
• 02:48The last
• 02:49few years, I've been working
• 02:50with scholars at Oxford
• 02:52and National
• 02:54University of Singapore,
• 02:56on harm reduction and ethical
• 02:58guidelines within psychedelics.
• 03:04So I have no disclosures
• 03:06to report.
• 03:09As you may well be
• 03:11aware, in twenty twenty three,
• 03:13the US FDA
• 03:14stated that psychedelic drugs have
• 03:16shown initial promise
• 03:18as potential treatments.
• 03:20However, these are still investigational
• 03:23products.
• 03:24They signified their willingness at
• 03:26that time to permit psychedelics
• 03:28clinical trials, but they voiced
• 03:29their caution
• 03:31and said that sponsors evaluating
• 03:33the therapeutic potential
• 03:35of these drugs
• 03:36should consider could should consider
• 03:39their unique characteristics
• 03:41when designing clinical
• 03:43studies.
• 03:45So they clearly highlighted
• 03:47uncertainty,
• 03:48the unknowns, and the distinct
• 03:50characteristics
• 03:52of psychedelics.
• 03:55And, indeed,
• 03:57some psychedelic trials have had
• 03:59had somewhat lackluster
• 04:00findings. In twenty twenty one,
• 04:03one widely anticipated
• 04:05study by Carhart Harris
• 04:07found that psilocybin was only
• 04:09marginally better than traditional treatments
• 04:11at relieving
• 04:13depression.
• 04:15And more recently, I'm sure
• 04:17you're all aware that the
• 04:18FDA denied Lycos Therapeutics application
• 04:21for MDMA
• 04:23assisted therapy,
• 04:24stressing the need for additional
• 04:26research.
• 04:29And,
• 04:30and the incoming administration,
• 04:32however,
• 04:33is signaling increased interest in
• 04:35access to psychedelics
• 04:37while also favoring deregulation.
• 04:40And
• 04:41deregulation
• 04:43reduces government power with the
• 04:45aim of enabling businesses to
• 04:47operate more freely and efficiently,
• 04:50actions which may foster market
• 04:52growth
• 04:53and innovation.
• 04:55And given the price of
• 04:57psychedelic sessions in Oregon's regulated
• 05:00psilocybin
• 05:01market, around twelve hundred per
• 05:03trip,
• 05:04and a potentially lucrative psychedelics
• 05:07market, psychedelic deregulation certainly offers
• 05:10numerous
• 05:11benefits.
• 05:13It could increase excess. It
• 05:15could lower costs, and it
• 05:17could create more above ground
• 05:19jobs.
• 05:20It might possibly,
• 05:22decrease some of the harms
• 05:23that are associated with the
• 05:25ever growing underground
• 05:27market.
• 05:28I'm aware of the numbers
• 05:30of of underground guides that
• 05:32have been growing since all
• 05:33of these training programs have
• 05:36increased in size in
• 05:38anticipation of,
• 05:39MDMA becoming
• 05:41legal.
• 05:42But,
• 05:43deregulation may be welcomed by
• 05:45many communities,
• 05:46including for profit drug developers
• 05:49and veterans advocacy groups who
• 05:51promote psychedelics for the treatment
• 05:54of
• 05:58PTSD. Others view regulation as
• 06:01the spirit of democratic reform,
• 06:04and that regulation
• 06:05can protect the public interest
• 06:07from corporate abuse.
• 06:09And it follows that deregulation
• 06:12of psychedelics may increase the
• 06:14likelihood of unethical practices,
• 06:16such as those long discussed
• 06:18by indigenous scholars like Yuria
• 06:20Saludwin,
• 06:22including a rise in exploitative
• 06:25psychedelics
• 06:26tourism and unsustainable
• 06:28foraging of their medicines, which
• 06:31makes them increasingly
• 06:32unavailable
• 06:34for local use.
• 06:37Deregulation
• 06:38may also decrease protections
• 06:40psychedelics
• 06:41users and reduce transparency
• 06:44on psychedelic organizational
• 06:46practices,
• 06:47which are factors that could
• 06:48contribute to increased harms and
• 06:51boundary violations.
• 06:55So the risks of deregulation
• 06:57may also be relevant
• 06:59in light of recent and
• 07:01under discussed findings on adverse
• 07:04outcomes
• 07:05and practices
• 07:06in psychedelics
• 07:08research.
• 07:11I'm not sure if anyone's
• 07:12aware of the Brykszema
• 07:14study or of Jules Evans'
• 07:17work, but I thought it
• 07:18would be helpful
• 07:20to,
• 07:21talk about some of their
• 07:22recent findings.
• 07:24A number of recent studies
• 07:26have uncovered flaws in psychedelics
• 07:29study design
• 07:31and provided greater awareness of
• 07:33the nature and frequency
• 07:35of adverse effects by psychedelics.
• 07:39For example, Brikszema
• 07:41and authors in twenty twenty
• 07:43two conducted a review
• 07:45of psychedelics clinical trials since
• 07:47two thousand.
• 07:49They,
• 07:50their analysis covered, I think,
• 07:52forty four articles across five
• 07:54hundred and ninety eight unique
• 07:56patients,
• 07:57and they found that adverse
• 07:58events were poorly defined and
• 08:00probably underreported
• 08:02in the literature due to
• 08:03study design.
• 08:06They also found the study's
• 08:07results may be biased due
• 08:09to their tendency to choose
• 08:11subjects with prior psychedelics experience.
• 08:14So these are subjects who
• 08:15understand
• 08:16the psychedelics experience and likely
• 08:18already had a positive psychedelics
• 08:21experience
• 08:22and had a desire to
• 08:23reengage.
• 08:24So,
• 08:26Briksima
• 08:27and authors recommend that future
• 08:29studies include a broader spectrum
• 08:32of subjects
• 08:33and to provide increased transparency
• 08:35on the timing and severity
• 08:38of adverse events.
• 08:39A proper understanding of adverse
• 08:41events is essential to understanding
• 08:44the range of responses to
• 08:46psychedelics
• 08:47and thereby essential to providing
• 08:51more accurate informed consent.
• 08:54So this may point to
• 08:56the need for some additional
• 08:57ethical scaffolding within trials and
• 09:00within practice
• 09:01to take the time to
• 09:03document adverse events and to
• 09:06include psychedelics'
• 09:07naive subjects within studies.
• 09:10And also to disclose the
• 09:12numbers of psychedelics'
• 09:14naive subjects and their rates
• 09:16of adverse effects when reporting
• 09:18findings.
• 09:20And, of course, others,
• 09:22certainly talk about the the
• 09:25importance of tracking
• 09:26longer term outcomes, and that's
• 09:29always a challenge in any
• 09:30study,
• 09:31but, should be encouraged.
• 09:34And,
• 09:34of course, you know, for
• 09:35years, the field has been
• 09:36focused on the potential benefits
• 09:38of psychedelics to really,
• 09:41right the ship and and
• 09:43push back on the narrative
• 09:45that psychedelics are so dangerous.
• 09:47And so some now are
• 09:48arguing that it's time to
• 09:50pay a bit more attention
• 09:51to understanding
• 09:52risks, especially
• 09:54long term risks.
• 09:56And indeed, the extent of
• 09:58risks to psychedelic use seem
• 10:00to not yet be fully
• 10:02delineated,
• 10:03including information about the predictors
• 10:05of adverse events
• 10:07or adverse events severity
• 10:10and duration.
• 10:12We also see racial disparities
• 10:15in outcomes within psychedelics clinical
• 10:18trials,
• 10:19which need further attention
• 10:20so that the potential benefits
• 10:22of psychedelics are not disproportionately
• 10:25experienced by only white participants.
• 10:29For white participants, MDMA and
• 10:31psilocybin
• 10:32use have conferred lowered odds
• 10:36of all distress and suicide
• 10:38suicidality
• 10:39outcomes,
• 10:40but racial and ethnic minority
• 10:42participants
• 10:43did not experience those associations.
• 10:46And these are findings by
• 10:48Matt Nock and Grant Jones
• 10:50in a twenty twenty two
• 10:52article in Scientific Reports.
• 10:57But,
• 10:58some other work really complements
• 11:01and, provides
• 11:03us a way forward. If
• 11:04you look at Monica Williams'
• 11:06work,
• 11:07I don't have
• 11:09her exact citations for the
• 11:12the the articles,
• 11:14that I'm talking about here.
• 11:15But we know that,
• 11:19we know that members of
• 11:20racial and ethnic minorities might
• 11:22not meet the stringent criteria
• 11:25of clinical trials,
• 11:26criteria that may be too
• 11:28restrictive.
• 11:29And so,
• 11:30Monica Williams,
• 11:32is beginning to examine
• 11:34how we can revise the
• 11:36criteria for studies and how
• 11:38we can do a much
• 11:39better job of recruiting
• 11:42black and brown populations.
• 11:44So she's written guidelines to
• 11:46expand diversity within psychedelic clinical
• 11:49trials, and,
• 11:50she's always happy to connect
• 11:52with PIs to help,
• 11:55navigate that space.
• 11:58So,
• 11:59seeking to examine the nature
• 12:01and predictors
• 12:03of adverse events during and
• 12:05after psychedelics experiences,
• 12:07Jules Evans and friends conducted
• 12:10a mixed methods
• 12:11study of over six hundred
• 12:13adults.
• 12:14And these were six hundred
• 12:16adults who experienced difficulties
• 12:18after
• 12:19using psychedelics.
• 12:21And they found that long
• 12:23term adverse effects can indeed
• 12:25be profound
• 12:26and may include derealization,
• 12:29depersonalization,
• 12:31fear, and anxiety.
• 12:32And they found that for
• 12:34approximately
• 12:35one third of the participants
• 12:38in their study, that problems
• 12:40persisted for over a year.
• 12:43And for a sixth, they
• 12:44endured for more than three
• 12:46years.
• 12:48And so,
• 12:52some subjects,
• 12:54are clearly experiencing
• 12:56post psychedelic difficulties that are
• 12:58so severe
• 12:59that they meet the criteria
• 13:01for PTSD.
• 13:03And we are not yet
• 13:05able to consistently know who's
• 13:08going to benefit from psychedelics
• 13:10and who might be the
• 13:12unlucky one who experiences harms,
• 13:15especially long term harms.
• 13:17We're also not yet able
• 13:19to consistently know for whom
• 13:21benefits will last
• 13:23and for how long.
• 13:25Sorry. Laurie? Yes. These last
• 13:27couple studies that, that have
• 13:29documented harms. So that survey
• 13:31was
• 13:32not just in regulated research
• 13:35contexts, but but recreational use
• 13:36in wild. Is that correct?
• 13:38And these are people who
• 13:39are self selected
• 13:40for having negative
• 13:42effects. Exactly. Yes. Okay. So
• 13:44important. So these numbers, like
• 13:45a third and a sixth,
• 13:46clearly document that this happens
• 13:48and is not rare, but
• 13:49they can't be generalized.
• 13:51Exactly. We cannot yes. Yes.
• 13:53Exactly.
• 13:54That it's very important. And
• 13:56and Jules and I are
• 13:57always so careful to say
• 13:58that, you know, this study
• 13:59was of people, you know,
• 14:01who who reported the difficulties.
• 14:03So there's, you know, there
• 14:05are his stats, and then
• 14:06there are adverse effects that
• 14:08are reported within trials that
• 14:10are much less than that.
• 14:13But those are the kinds
• 14:14of studies that are
• 14:16quite picky about who they
• 14:17choose. And so we don't
• 14:19really know what to tell
• 14:21people on informed consent forms
• 14:23because it's gonna be somewhere
• 14:25probably within that range of
• 14:27four percent
• 14:28and one third. Right. Yeah.
• 14:30Which is incredibly broad. But,
• 14:33but he's,
• 14:35follow his work because he's
• 14:37he's been doing some really,
• 14:39important work, and he keeps
• 14:41extending it every day. He's
• 14:43a prolific writer that I
• 14:45encourage you all to follow.
• 14:50So
• 14:53part of what Jewel says
• 14:55is that whatever psychedelics can
• 14:57alleviate,
• 14:58they can also cause.
• 15:01So psychedelics
• 15:02can indeed help some people
• 15:04be back in touch with
• 15:05their pretrauma
• 15:06selves, which is entirely profound
• 15:08and perhaps unlike anything we
• 15:10have within current mental health
• 15:12treatment, but Evans calls our
• 15:13attention to psychedelics
• 15:15as what he calls a
• 15:16double edged sword.
• 15:18While psychedelics may be used
• 15:20in the treatment of anxiety
• 15:22or PTSD,
• 15:24psychedelics may also cause anxiety
• 15:26or bring on PTSD symptoms
• 15:29in others.
• 15:31Similarly, psychedelics may provide clarity
• 15:34and
• 15:35profound,
• 15:36personal meaning,
• 15:37but they may also plunge
• 15:39users into existential confusion,
• 15:42and sometimes for long long
• 15:44term
• 15:45periods.
• 15:46So this characterization
• 15:47of the unpredictable
• 15:48effects of psychedelics is not
• 15:50widely known
• 15:52by potential
• 15:53users.
• 15:54And I I do have
• 15:55to say just
• 15:57anecdotally, the more people
• 15:59who within my circles who
• 16:01learn that I am involved
• 16:03in the ethics of psychedelics,
• 16:05the more
• 16:06they approach me and let
• 16:08me know
• 16:09that that they have had
• 16:10experiences that have left them
• 16:12deeply shattered and that they
• 16:14are hoping that,
• 16:17that there will be more
• 16:18attention to trying to understand
• 16:20why some people's lives are
• 16:22really shattered. Even though it
• 16:24it does seem to be
• 16:25a small minority,
• 16:26but it has such an
• 16:27impact on some people's lives
• 16:29that they are unable to
• 16:30hold down jobs and that
• 16:31they really do suffer.
• 16:36And so Jules, Evans,
• 16:39and authors
• 16:40call for increased support and
• 16:42coping mechanisms for those who
• 16:44are suffering
• 16:45from these long term harms,
• 16:47including education on the kinds
• 16:49of practices that can address
• 16:51long term adverse effects.
• 16:57So Raison
• 16:58and friends also explored the
• 17:01prevalence of harms and adverse
• 17:03effects
• 17:04and found that they are
• 17:05largely unknown and underdocumented
• 17:07within trials,
• 17:09that they are likely to
• 17:11increase as exclusion criteria are
• 17:13relaxed within clinical trials.
• 17:16And that thirteen percent they
• 17:18found thirteen percent of naturalistic
• 17:21users endorsed having experienced at
• 17:23least one harm.
• 17:26And, you know, I should
• 17:28say too that in my
• 17:29discussions with Jules, he does
• 17:31also bring up how
• 17:33people who experience
• 17:35long term adverse effects
• 17:37may indeed say that, you
• 17:39know, after some period of
• 17:40time that the psychedelics experience
• 17:42was still worth it
• 17:44and,
• 17:45and help them through their
• 17:47traumas,
• 17:48but that they weren't expecting
• 17:50that the journey would be
• 17:51so long or so painful.
• 17:55And then going back to
• 17:57Raison's study,
• 17:58he found serious adverse effects
• 18:01around four percent
• 18:02within a recent review of
• 18:04a hundred and fourteen studies.
• 18:09And I'm sure you're all
• 18:11aware
• 18:12of the,
• 18:14example
• 18:15of derealization
• 18:16that got a lot of
• 18:18news.
• 18:19Derealization
• 18:20is an adverse effect from
• 18:22psychedelics. It's that feeling of
• 18:24being so detached from your
• 18:26surroundings that you almost feel
• 18:28like you're in a movie
• 18:29or a dream.
• 18:31There was an off duty
• 18:33Alaska Airlines pilot
• 18:35accused of attempting to disable
• 18:37a plane's engines, and he
• 18:38was indeed mid flight trying
• 18:40to disable those engines because
• 18:42he believed that he was
• 18:43dreaming,
• 18:44and he thought he'd be
• 18:45able to escape the dream
• 18:47by causing the plane to
• 18:49crash.
• 18:50And he mentioned that he
• 18:51had taken psilocybin
• 18:53forty eight hours before that
• 18:55incident.
• 18:58So
• 18:59so part of the reason
• 19:00I bring that up is
• 19:01that the public are starting
• 19:03to become a bit more
• 19:05aware of what derealization
• 19:06really means.
• 19:09But then there are some
• 19:11other aspects of post trip
• 19:13struggles
• 19:14that,
• 19:15may relate as well to
• 19:17people lacking
• 19:18proper support structures
• 19:20after participating
• 19:22in trials. And Yuria Saladin's
• 19:25work is
• 19:28quite fascinating
• 19:29and pivotal to our conversations.
• 19:32She talks about how within
• 19:34psychedelics therapy trials, we are
• 19:36indeed borrowing from indigenous practices,
• 19:39but only partly so,
• 19:42that
• 19:44you cannot have without she
• 19:46talks about the complete sense
• 19:48of identity change without the
• 19:50container to process
• 19:51it poses
• 19:52risks, and that there's this
• 19:54post trip support
• 19:56that lacks an understanding
• 19:58from the broader community.
• 20:01Whereas within,
• 20:03many indigenous
• 20:04communities, everyone's aware of someone
• 20:07having gone through their psychedelics
• 20:09experience and needing that support,
• 20:12and how to support them
• 20:14through that. And she finds
• 20:16that clinical trials that have
• 20:18one month follow ups,
• 20:20are not doing enough to
• 20:23support,
• 20:24their subjects that she and
• 20:26she says that that is
• 20:27not real integration.
• 20:29Urges us to consider what
• 20:31true responsibility
• 20:32within these studies means and
• 20:34to bring indigenous voices more
• 20:36into these discussions.
• 20:42So,
• 20:43given the findings discussed above,
• 20:46our
• 20:47current policies and practices may
• 20:49need additional scaffolding so we
• 20:51don't fall short of our
• 20:53ethical obligations
• 20:55to care for psychedelics users.
• 20:58For example, we might want
• 21:00to look at consent guidelines
• 21:02and how consistently
• 21:04they are informing research subjects
• 21:06and psychedelics users in places
• 21:08like Oregon
• 21:10of potential harms so that
• 21:11they may gain a more
• 21:13realistic understanding
• 21:14of possible outcomes. And I
• 21:17know that there are a
• 21:18bunch of folks who are
• 21:19looking into
• 21:20alternatives
• 21:21to the consent form and
• 21:23a conversation
• 21:24that starts really closely to
• 21:27the actual study start date.
• 21:29But maybe there can be
• 21:31videos or some other ways
• 21:33of of helping folks to
• 21:36more fully understand,
• 21:38the risks and the benefits
• 21:41that they may indeed experience.
• 21:45And potential users should also
• 21:47understand that the field is
• 21:48presently unable to determine who
• 21:50is more predisposed
• 21:52to experience severe
• 21:54adverse
• 21:55effects.
• 21:56So research labs and facilitators
• 21:59may also wish to have
• 22:00direct discussions with potential users
• 22:02about how they would face
• 22:04adverse effects. You know, do
• 22:06they have the financial means
• 22:08to take time off of
• 22:09work and pay for private
• 22:11integration sessions?
• 22:13Do they have a support
• 22:14system to care for them
• 22:15if they have that you
• 22:17know, when they have that
• 22:18extended state of vulnerability?
• 22:20Because psychedelics
• 22:21opens us up for the
• 22:23potential of healing, but that
• 22:25also opens us up for
• 22:26the potential
• 22:27to,
• 22:28have boundary violations,
• 22:30in in all sorts of
• 22:32settings.
• 22:35So these are some of
• 22:36the things we might think
• 22:38about.
• 22:40And circling back to under
• 22:42the new administration,
• 22:44the role of subject protections
• 22:47and consumer and indigenous protections
• 22:51may indeed
• 22:52likely fall to local and
• 22:54state governments and private parties
• 22:56like
• 22:57these,
• 22:58you know,
• 23:00the the folks that provide
• 23:01the facilitation
• 23:03services.
• 23:04So resource limited jurisdictions
• 23:07may turn to
• 23:08Oregon's model to identify
• 23:11a few achievable
• 23:12regulations
• 23:13or guidelines.
• 23:15There are safe and affordable
• 23:18psychedelics, which may also depend
• 23:20more heavily on organizations
• 23:22electing to follow various ethical
• 23:25guidelines.
• 23:26So this speaks to the
• 23:27need for strong
• 23:28organizational
• 23:30ethics frameworks,
• 23:32and the burden will also
• 23:33likely fall more heavily on
• 23:35potential users to investigate
• 23:38companies on their own.
• 23:43The field could also benefits,
• 23:46from some more concrete guidance
• 23:48on how to explain the
• 23:49range of post trip integration
• 23:51services.
• 23:54Integration services may help users
• 23:56recover from or process their
• 23:58trip, but they can be
• 24:00quite expensive and they are
• 24:02usually not covered by clinical
• 24:04trials, right, if you need
• 24:05more than the couple sessions
• 24:07at the end of a
• 24:08trial.
• 24:09And so,
• 24:11what's, you know, is has
• 24:13what happens sometimes is that
• 24:15the perspectives
• 24:16of these,
• 24:17private integration guides
• 24:20may often differ from mainstream
• 24:22culture, which may further alienate
• 24:25some of the people seeking
• 24:26services.
• 24:28For example, some integration
• 24:30guides believe that post trips
• 24:32struggles relate to the the
• 24:35metaphysical
• 24:35presence of an entity
• 24:37within the subject.
• 24:39And this belief may be
• 24:41quite disconcerting or unhelpful to
• 24:43some people
• 24:44seeking guidance. And it might
• 24:46just
• 24:47cause them to think, you
• 24:48know, this is this isn't
• 24:49working for me. And so
• 24:50helping subjects to understand the
• 24:53kinds of questions they should
• 24:54ask when seeking integration specialists
• 24:57would often prevent,
• 24:59delays in treatment.
• 25:01We know that many subjects
• 25:03who do have,
• 25:05struggle with integration
• 25:07often do return to their
• 25:08PI and say, you know,
• 25:09I know that
• 25:11there's no there are no
• 25:12more integration
• 25:13sessions for me within your
• 25:15lab, but
• 25:16who do I turn to
• 25:17in this moment? And how
• 25:19do I go about trying
• 25:21to select a guide? So,
• 25:23if we're able to,
• 25:26as a field,
• 25:27be a little bit more
• 25:28organized about pointing them the
• 25:30way to resources.
• 25:31It could be,
• 25:33quite helpful to curtail the
• 25:35the
• 25:36severity
• 25:37of their,
• 25:39of their struggles.
• 25:41And, you know, I think
• 25:42educating policymakers
• 25:44and the public will be
• 25:45increasingly important,
• 25:46especially given widely touted yet
• 25:48unsubstantiated
• 25:49claims by scholars and advocates
• 25:52in the media.
• 25:53We all know that some
• 25:55folks frequently claim that psychedelics
• 25:56is going to create a
• 25:58world of net zero trauma
• 25:59by twenty seventy.
• 26:01While, another scholar recently stated
• 26:04that psychedelics may be the
• 26:06master key for reopening
• 26:08virtually any critical period of
• 26:10neural development.
• 26:12These claims are reported in
• 26:14the press, and they discourage
• 26:16a nuanced understanding
• 26:17of psychedelics.
• 26:19Public communications
• 26:21can help to counter the
• 26:22hype
• 26:23so that users' expectations
• 26:25can be more in line
• 26:27with outcomes.
• 26:29Physicians and first responders
• 26:31getting educated as well would
• 26:33also help to promote understanding
• 26:35and treatment of patients experiencing
• 26:38adverse effects. As it is,
• 26:40Many,
• 26:42patients talk about how they're,
• 26:44you know, they're really uncomfortable
• 26:46going to their physicians and
• 26:48saying that they might try
• 26:50psychedelics or that they're having
• 26:51adverse event events from psychedelics
• 26:54because they're worried about the
• 26:56stigma.
• 26:57They're worried that their physician
• 26:58might not be psychedelics friendly.
• 27:03You might also be aware
• 27:04of,
• 27:06Anderson's recent,
• 27:08I think it was an
• 27:09essay in the Lancet Psychiatry,
• 27:12he noted that even conservative
• 27:14individuals can become wildly enthusiastic
• 27:18about the potential of psychedelics
• 27:20to heal
• 27:21and transform.
• 27:23So,
• 27:25I think, you know, it
• 27:26it serves everyone well when
• 27:28we are able to have,
• 27:30a balanced conversation
• 27:32about the potential benefits
• 27:35of these very powerful substances.
• 27:39David Yaden
• 27:41does a lot of
• 27:42psychedelics
• 27:43research at Johns Hopkins.
• 27:46And, just about two years
• 27:47ago now, he wrote about
• 27:49this psychedelic hype bubble.
• 27:51He expresses concerns about unsubstantiated
• 27:54claims that psychedelics can,
• 27:57for instance, cure mental illness,
• 28:00solve
• 28:01massive social problems,
• 28:03and create a psychedelic
• 28:05utopia.
• 28:06So he and others argue
• 28:08that psychedelics that scholars should
• 28:10be the ones that burst
• 28:11this bubble
• 28:13because he says, of course,
• 28:15that psychedelics research
• 28:17is still in its infancy
• 28:18and that
• 28:19we can be hopeful, but
• 28:21we ought to exercise
• 28:23restraint in our projections.
• 28:30And so since an understanding
• 28:32of the benefits and harms
• 28:33of psychedelics is contingent
• 28:35on future research, may we
• 28:37may also wish to consider
• 28:39whether a fund could be
• 28:41established to subsidize care for
• 28:43subjects who experience
• 28:45significant
• 28:46long term
• 28:47adverse effects from participation in
• 28:49clinical trials.
• 28:50This would respond to Evan's
• 28:53and friend's assessment that it
• 28:54is urgent to factor in
• 28:56support for this population,
• 28:59especially as the numbers of
• 29:00psychedelic scusers
• 29:02increase.
• 29:04So subjects whose participation
• 29:06contributes
• 29:08to furthering psychedelic science
• 29:10should not be left to
• 29:12endure long term adverse effects
• 29:14on their own. The treatment
• 29:16may be costly, and some
• 29:17subjects may be so incapacitated
• 29:19that they can't work.
• 29:21And, of course, funding
• 29:23may be a hurdle, but
• 29:25perhaps
• 29:26we'll have some for
• 29:27for profit sponsors of research
• 29:29that may step forward to,
• 29:32support integration circles.
• 29:36So,
• 29:39we, being the Hopkins Oxford
• 29:41Psychedelic Ethics Working Group,
• 29:45established initial framing for ethical
• 29:48guidelines in a recent consensus
• 29:50statement.
• 29:51We,
• 29:53got together with,
• 29:55a group of diverse participants,
• 29:58and
• 30:00we had a meeting where
• 30:01there were keynotes given by
• 30:03indigenous scholars and psychiatrists,
• 30:05and other attendees included
• 30:07ethicists and lawyers and psychedelic
• 30:09scientists and anthropologists
• 30:11and entrepreneurs and
• 30:14philosophers and harm reduction actors
• 30:16and so forth. And we
• 30:17put together this consensus statement
• 30:20that addresses,
• 30:22what we feel are necessary
• 30:25next steps in terms of
• 30:26consent,
• 30:28equity,
• 30:29the need for education,
• 30:32standards for professional conduct,
• 30:34and, hopefully, the development of
• 30:36some media guides to support
• 30:38reporters
• 30:39that,
• 30:42to help them more accurately,
• 30:44discuss
• 30:45psychedelics.
• 30:49And finally, you know, just
• 30:50looking forward at twenty twenty
• 30:52five, the prospect
• 30:53of using psychedelic
• 30:56assisted therapies to treat
• 30:58adolescents experiencing
• 31:00severe mental illnesses
• 31:02has recently
• 31:03generated
• 31:04increased interest
• 31:06among some mental health professionals
• 31:08and researchers and ethicists
• 31:10and concern
• 31:12among others.
• 31:14And so if psychedelics
• 31:15are approved as medicine, they
• 31:18may indeed be used off
• 31:19label in adolescent health care
• 31:22like other forms of adolescent
• 31:24health care. And so
• 31:25this raises an ethical question
• 31:27as to whether and how
• 31:30psychedelics
• 31:30ought to be studied in
• 31:32this population
• 31:33before clinical
• 31:35use.
• 31:38Many ethical issues, as you
• 31:39can imagine, emerge when we
• 31:41contemplate the translation of psychedelic
• 31:44therapy research into the adolescent
• 31:47context.
• 31:48If adolescents
• 31:49are to be included in
• 31:51well designed trials in this
• 31:52area,
• 31:53research should likely begin with
• 31:55carefully selected,
• 31:57primarily older adolescents
• 31:59face facing special circumstances,
• 32:02perhaps,
• 32:04such as,
• 32:05cancer patients with terminal illness
• 32:08to help,
• 32:09address their angst at end
• 32:11of life,
• 32:12to minimize the risk of
• 32:14net harms to the patient
• 32:16while also shedding light on
• 32:18the potential benefits and harms
• 32:20of psychedelic
• 32:21assisted therapy
• 32:22within this
• 32:24population.
• 32:28We should also consider
• 32:30collaborating
• 32:31with underrepresented
• 32:33communities
• 32:34to facilitate
• 32:35welcoming spaces for all research
• 32:38subjects,
• 32:39and also more precisely
• 32:41determine the risks and benefits
• 32:43of psychedelics,
• 32:45hopefully being able to track
• 32:47conduct some larger scale studies
• 32:49that will track longer
• 32:51term
• 32:51outcomes.
• 32:54And just thinking a little
• 32:55bit more about informed consent,
• 32:58which I've touched upon here
• 32:59and there, but, you know,
• 33:01how it really does require
• 33:03hype management.
• 33:04It requires a bit of
• 33:05extra time. It requires
• 33:08a lot of education,
• 33:10by the subject, and sometimes
• 33:11the subject's family,
• 33:13and the importance of us
• 33:15talking about,
• 33:17their day to day support
• 33:18structures to determine whether
• 33:20their post trip integration
• 33:23could bolster their healing process.
• 33:28And I talk about,
• 33:30some of these,
• 33:32harms and benefits in
• 33:35a recent,
• 33:36article in a job.
• 33:39And whenever
• 33:40I give a psychedelics talk,
• 33:42I always try to remember
• 33:44to link you with Jules
• 33:45Evans' Psychedelic Safety Research Group,
• 33:49which does a lot of
• 33:50great work. So his contact
• 33:51information is here on the
• 33:53left.
• 33:54And I,
• 33:55also
• 33:56like to always point out
• 33:58the Fireside Project and the
• 34:00ISER's support center.
• 34:02So if you or someone
• 34:04you know needs post psychedelic
• 34:06support, I'm told that these
• 34:08are good resources, although I
• 34:10do not know them personally.
• 34:14And, of course, I would
• 34:15be remiss if I don't
• 34:16point everyone to,
• 34:19a program I direct every
• 34:20summer in bioethics.
• 34:22All are welcome.
• 34:25I have short programs and
• 34:26long programs, and we have,
• 34:28all sorts of bioethics education
• 34:31we offer throughout
• 34:32May and June and July.
• 34:35So in closing,
• 34:38psychedelics can indeed provide transcendent
• 34:41experiences
• 34:42and may provide healing to
• 34:44many individuals who may otherwise
• 34:47suffer
• 34:48severe depression,
• 34:49anxiety, and PTSD.
• 34:52And if some thoughtful protections
• 34:53are enacted through institutional policies
• 34:56and state mandates,
• 34:57I'm hopeful that the harms
• 34:59from a deregulated
• 35:01environment could indeed be reduced.
• 35:04So thank you all for
• 35:05having me here today, and
• 35:07I will stop sharing my
• 35:09screen.